Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)

Sekisui XenoTech,LLC
Posted on: 05 Dec 18
Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)

Sekisui XenoTech has created a Scientific Advisory Board (SAB) of renowned scientists and thought leaders in the pharmaceutical industry.

Initially this board will be made up of four experts specializing in Absorption, Distribution, Metabolism and Excretion (ADME) studies, as well as Drug Metabolism and Pharmacokinetics (DMPK). The board will be led by Dr. Brian Ogilvie, Vice President of Scientific Consulting for Sekisui XenoTech.

Dr. Ogilvie sought out thought leaders that have distinctive perspectives on the pharmaceutical industry that have been formulated from their independent expertise and numerous years of experience. Through their insight Sekisui XenoTech will be guided to better serve the industry by anticipating growth trends, scientific innovation and ultimately the greater needs of its customers.

The SAB consists of: Dr. Griff Humphreys, Principal with Aranmore Pharma Consulting; Dr. Jane Kenny, Associate Director/Principal Scientist at Genentech; Dr. Ajay Madan, Vice President, Development for Crinetics Pharmaceuticals; and Dr. Larry Wienkers, Owner of Wienkers Consulting, LLC. For more information on the SAB members, please consult Sekisui XenoTech’s website.

“I am excited to bring this group together. The combination of our internal knowledge and 25 years of experience in the industry with the infusion of the extensive expertise and well-respected knowledge brought by this SAB will serve to set Sekisui XenoTech apart as the leader in in vitro DDI and ADME testing services and products.” stated Dr. Ogilvie.

About Sekisui XenoTech
Sekisui XenoTech, LLC is a global Contract Research Organization utilized by 98% of top pharma companies and numerous other organizations. For 25 years, the company has offered proven drug development expertise, providing an ever-evolving selection of cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADME Toxand pharmacology, in vivo ADME Tox and QWBA, metabolite ID and production, bioanalytical services and consulting. Sekisui XenoTech's product selection includes a wide range of high-quality unique and standard reagents, including subcellular fractions, hepatocytes, media, tissue samples, cell lines, recombinant enzymes, substrates, metabolites and more. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at www.xenotech.com.

For more information:
www.xenotech.com/company/scientific-advisory-board

Editor's Details

Michael Millhollen
Sekisui XenoTech, LLC
www.xenotech.com
9134387450
mmillhollen@xenotechllc.com

Last updated on: 05/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.